Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 iBio Expands COVID-19 Vaccine Collaboration | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

iBio Expands COVID-19 Vaccine Collaboration

Now includes the Infectious Disease Research Institute to help lead pre-clinical development and clinical trial oversight

By: Contract Pharma

Contract Pharma Staff

iBio, a biologics contract manufacturing organization and biotechnology innovator, has signed two Master Services Agreements (MSAs) and a Memorandum of Understanding (MoU) with the Infectious Disease Research Institute (IDRI) in support of iBio’s SARS-CoV-2 Virus-Like Particle (VLP) vaccine development.
 
Under the MSAs, IDRI will support pre-clinical development and provide clinical trial oversight, while iBio will provide process development and manufacturing services to IDRI, as needed. Additionally, the MoU calls for iBio and IDRI to establish a separate, additional agreement within the next 60 days if the company opts to include one of IDRI’s novel adjuvants in the COVID-19 vaccine development program (IBIO-200). The MSAs and the MoU integrate IDRI into iBio’s collaboration with the Texas A&M University System to create a strong partnership that brings deep experience and advanced technologies and capabilities to the task of moving IBIO-200 into the clinic.
 
“We are delighted to have IDRI contribute its deep understanding of infectious diseases and vaccine development expertise to the team,” said Tom Isett, co-chairman and chief executive officer, iBio. “We are also looking forward to evaluating the novel adjuvants in IDRI’s portfolio that may deliver even greater immunostimulatory effects. A more potent antigen-adjuvant combination would further increase our projected manufacturing capacity for production of a vaccine for COVID-19 disease.”
 
Corey Casper, chief executive officer, IDRI, and clinical professor of medicine and global health, University of Washington, said, “We are excited to be a partner in the development of IBIO-200. Combining iBio’s VLP antigen with an IDRI adjuvant provides for promising safety and efficacy characteristics, and importantly, the ready ability to scale-up manufacturing to help meet the projected global demand for a suitable vaccine.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters